Literature DB >> 9869480

Cardiac death prediction and impaired cardiac sympathetic innervation assessed by MIBG in patients with failing and nonfailing hearts.

T Nakata1, K Miyamoto, A Doi, H Sasao, T Wakabayashi, H Kobayashi, K Tsuchihashi, K Shimamoto.   

Abstract

BACKGROUND: Although cardiac sympathetic nerve dysfunction is related to poor clinical outcome, a critical sympathetic dysfunction level for predicting cardiac death is still unclear. The current study was designed to investigate which indices derived from metaiodobenzylguanidine (MIBG) imaging have prognostic value compared with clinical and cardiac function variables, and to determine the threshold of cardiac MIBG activity for identifying patients likely to suffer cardiac death in both failing and nonfailing hearts. METHODS AND
RESULTS: Myocardial I-123-MIBG activity was quantified as a heart-to-mediastinum ratio in 414 consecutive patients, 173 (42%) of whom had symptomatic heart failure. After cardiac function measurements, patients were followed up with an end-point of cardiac or noncardiac death. During a mean follow-up period of 22 months, 37 cardiac deaths occurred: 23 resulted from heart failure, 9 were sudden cardiac deaths, and 5 were fatal myocardial infarctions. Multivariate analysis using the Wald chi2 and the Cox proportional hazard model revealed that late heart-to-mediastinum ratio, the use of nitrates, early heart-to-mediastinum ratio, and left ventricular ejection fraction were independent predictors of cardiac death; late heart-to-mediastinum ratio, New York Heart Association (NYHA) class, the presence of previous myocardial infarction, and age were independent predictors of heart failure and sudden cardiac death. Late heart-to-mediastinum ratio was the most powerful predictor of overall cardiac death among the variables. The Kaplan-Meier analysis showed that a late heart-to-mediastinum ratio of 1.74 or less, age greater than 60 years, the presence of myocardial infarction, and NYHA functional class 3 or 4 strongly indicated poor clinical outcomes. Furthermore, the more powerful incremental prognostic values were obtained by using MIBG imaging in combination with conventional clinical variables.
CONCLUSIONS: Impaired cardiac sympathetic innervation assessed by MIBG activity has the greatest potential for predicting cardiac death and may be useful for identifying a threshold level for selecting patients at risk for death by heart failure, sudden cardiac death, and fatal myocardial infarction.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9869480     DOI: 10.1016/s1071-3581(98)90112-x

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   5.952


  18 in total

1.  Cardiac sympathetic nerve function in congestive heart failure.

Authors:  G Eisenhofer; P Friberg; B Rundqvist; A A Quyyumi; G Lambert; D M Kaye; I J Kopin; D S Goldstein; M D Esler
Journal:  Circulation       Date:  1996-05-01       Impact factor: 29.690

2.  Clinical and hemodynamic correlates of sympathetic nerve activity in normal humans and patients with heart failure: evidence from direct microneurographic recordings.

Authors:  D W Ferguson; W J Berg; J S Sanders
Journal:  J Am Coll Cardiol       Date:  1990-11       Impact factor: 24.094

3.  Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failure.

Authors:  T B Levine; G S Francis; S R Goldsmith; A B Simon; J N Cohn
Journal:  Am J Cardiol       Date:  1982-05       Impact factor: 2.778

4.  Regional cardiac sympathetic nerve dysfunction and the diagnostic efficacy of metaiodobenzylguanidine tomography in stable coronary artery disease.

Authors:  T Nakata; K Nagao; K Tsuchihashi; A Hashimoto; S Tanaka; O Iimura
Journal:  Am J Cardiol       Date:  1996-08-01       Impact factor: 2.778

5.  Myocardial adrenergic nervous activity is intensified in patients with heart failure without left ventricular volume or pressure overload.

Authors:  Y Imamura; H Ando; T Ashihara; T Fukuyama
Journal:  J Am Coll Cardiol       Date:  1996-08       Impact factor: 24.094

6.  Quantitative analysis of 123I-meta-iodobenzylguanidine (MIBG) uptake in hypertrophic cardiomyopathy.

Authors:  K Nakajima; H Bunko; J Taki; M Shimizu; A Muramori; K Hisada
Journal:  Am Heart J       Date:  1990-06       Impact factor: 4.749

7.  Metaiodobenzylguanidine to map scintigraphically the adrenergic nervous system in man.

Authors:  J C Sisson; B Shapiro; L Meyers; S Mallette; T J Mangner; D M Wieland; J V Glowniak; P Sherman; W H Beierwaltes
Journal:  J Nucl Med       Date:  1987-10       Impact factor: 10.057

8.  Abnormal I-123 metaiodobenzylguanidine myocardial washout and distribution may reflect myocardial adrenergic derangement in patients with congestive cardiomyopathy.

Authors:  E B Henderson; J K Kahn; J R Corbett; D E Jansen; J J Pippin; P Kulkarni; V Ugolini; M S Akers; C Hansen; L M Buja
Journal:  Circulation       Date:  1988-11       Impact factor: 29.690

9.  Predictors of total mortality and sudden death in mild to moderate heart failure. Captopril-Digoxin Study Group.

Authors:  A Gradman; P Deedwania; R Cody; B Massie; M Packer; B Pitt; S Goldstein
Journal:  J Am Coll Cardiol       Date:  1989-09       Impact factor: 24.094

10.  Noninvasive detection of cardiac sympathetic nervous dysfunction in diabetic patients using [123I]metaiodobenzylguanidine.

Authors:  M Mäntysaari; J Kuikka; J Mustonen; K Tahvanainen; E Vanninen; E Länsimies; M Uusitupa
Journal:  Diabetes       Date:  1992-09       Impact factor: 9.461

View more
  51 in total

1.  I-123 MIBG scintigraphy in idiopathic dilated cardiomyopathy: where next?

Authors:  Kevin C Allman; Avijit Lahiri
Journal:  J Nucl Cardiol       Date:  2002 Jan-Feb       Impact factor: 5.952

Review 2.  MIBG imaging.

Authors:  Amar D Patel; Ami E Iskandrian
Journal:  J Nucl Cardiol       Date:  2002 Jan-Feb       Impact factor: 5.952

Review 3.  Radionuclide imaging of cardiac autonomic innervation.

Authors:  Sang Yong Ji; Mark I Travin
Journal:  J Nucl Cardiol       Date:  2010-08       Impact factor: 5.952

Review 4.  Role of nuclear cardiac imaging in myocardial infarction: postinfarction risk stratification.

Authors:  John J Mahmarian; Girish Dwivedi; Tultul Lahiri
Journal:  J Nucl Cardiol       Date:  2004 Mar-Apr       Impact factor: 5.952

Review 5.  Cardiac neurotransmission SPECT imaging.

Authors:  Albert Flotats; Ignasi Carrió
Journal:  J Nucl Cardiol       Date:  2004 Sep-Oct       Impact factor: 5.952

6.  Quantitative I-123 mIBG SPECT in differentiating abnormal and normal mIBG myocardial uptake.

Authors:  Ji Chen; Russell D Folks; Liudmila Verdes; Daya N Manatunga; Arnold F Jacobson; Ernest V Garcia
Journal:  J Nucl Cardiol       Date:  2011-12-07       Impact factor: 5.952

7.  Norepinephrine spillover during exercise as a novel parameter to evaluate the severity of heart failure.

Authors:  Miyuki Ando; Takeshi Yamamoto; Akihiro Hino; Takashi Sato; Yasuma Nakamura; Masunori Matsuzaki
Journal:  J Nucl Cardiol       Date:  2010-05-26       Impact factor: 5.952

Review 8.  The role of radionuclide imaging in heart failure.

Authors:  Vinay Gulati; Gilbert Ching; Gary V Heller
Journal:  J Nucl Cardiol       Date:  2013-12       Impact factor: 5.952

Review 9.  Survival analysis and regression models.

Authors:  Brandon George; Samantha Seals; Inmaculada Aban
Journal:  J Nucl Cardiol       Date:  2014-05-09       Impact factor: 5.952

Review 10.  Cardiac metaiodobenzylguanidine imaging and heart failure.

Authors:  Tomoaki Nakata; Akiyoshi Hashimoto; Hirohito Sugawara
Journal:  Curr Heart Fail Rep       Date:  2013-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.